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Abstract
A major obstacle in treating drug addiction is the severity of opiate withdrawal syndrome, which can lead to unwanted
relapse. Mitragynine is the major alkaloid compound found in leaves of Mitragyna speciosa, a plant widely used by opiate
addicts to mitigate the harshness of drug withdrawal. A series of experiments was conducted to investigate the effect of
mitragynine on anxiety behavior, cortisol level and expression of stress pathway related genes in zebrafish undergoing
morphine withdrawal phase. Adult zebrafish were subjected to two weeks chronic morphine exposure at 1.5 mg/L,
followed by withdrawal for 24 hours prior to tests. Using the novel tank diving tests, we first showed that morphine-
withdrawn zebrafish display anxiety-related swimming behaviors such as decreased exploratory behavior and increased
erratic movement. Morphine withdrawal also elevated whole-body cortisol levels, which confirms the phenotypic stress-like
behaviors. Exposing morphine-withdrawn fish to mitragynine however attenuates majority of the stress-related swimming
behaviors and concomitantly lower whole-body cortisol level. Using real-time PCR gene expression analysis, we also showed
that mitragynine reduces the mRNA expression of corticotropin releasing factor receptors and prodynorphin in zebrafish
brain during morphine withdrawal phase, revealing for the first time a possible link between mitragynine’s ability to
attenuate anxiety during opiate withdrawal with the stress-related corticotropin pathway.
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Introduction
Drug addiction is a disorder encompassing compulsive drug use
and the inability to control drug intake [1]. Repeated exposure to
drugs eventually results in initiation of physiological homeostatic
adaptations to counter the undesirable effects of the exposure [2].
Upon cessation of drug intake, either voluntary or involuntary, the
body will rapidly metabolize and clear the drug. However, the
body’s homeostatic counter adaptations do not diminish as
rapidly, resulting in a complex phenomenon known as drug
withdrawal [3]. Clinical symptoms associated with withdrawal
include anxiety, headache, seizures, aches, hallucinations or
influenza-like syndromes. The desire to avoid and escape from
the aversive symptoms of withdrawal can unwantedly lead to
opiate seeking, resulting in relapse. Hence, a major goal in
addiction treatment is to relieve the severity of opiate withdrawal
symptoms. Administration of opioid agonists such as methadone
and buprenorphine are the most commonly used treatment
against opioid withdrawal [4]. However long term usage of these
opiate-like substances might instigate another phase of undesirable
opiate dependence and abuse [5]. Natural products are a potential
source of novel and safer compounds useful for drug withdrawal
management [6]. Elsewhere, there are documented cases of
herbal-based medicines as effective remedy in drug addiction
treatment [7,8].
Mitragyna speciosa Kroth or ‘Kratom’, a native Southeast Asia
plant, has a well-documented history as remedy against various
ailments including diarrhea, cough, muscular pain and fatigue [9].
M. speciosa is also frequently used by drug addicts seeking for relief
during opioid withdrawal stage [10]. While the use of M. speciosa is
illegal in Thailand, Malaysia, South Korea and Australia, it is as
source of unregulated ‘legal high’ in the UK and USA [11].
Among contributing factors are the lower cost of the plant material
as compared to buprenorphine and the widespread availability of
Kratom vendors [12]. At least 25 alkaloid compounds have been
isolated from Kratom leaves [13]. Mitragynine, an indole alkaloid,
is the foremost compound present in Kratom leaf extracts.
Collectively, studies have shown that mitragynine possess the
ability to suppress withdrawal syndrome, together with antinoci-
ceptive and antidepressant properties [14,15,16]. However, there
is still a paucity of understanding on how mitragynine exerts these
effects.
The zebrafish is gaining reputation as an advantageous model
for elucidating the neurobiology of drug addiction and withdrawal
[17]. Phenotypically, zebrafish show robust place preference
behavior when exposed to morphine [18,19]. The potential of
zebrafish was further validated by evidence showing addiction-
induced dopaminergic projections in the zebrafish forebrain
analogous to the mammalian mesolimbic system [20]. Withdrawal
from psychotropic drugs such as morphine, diazepam and caffeine
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endocrine response in zebrafish [17]. The influence of sex
differences on withdrawal syndrome in zebrafish also parallels
findings in rodents and human [21]. Other positive factors
accompanying the use of zebrafish are the existence of useful tools
such as genetic manipulations, useful mutant strains and
amenability to the development of high-throughput screening
assays.
In mammals, the corticotropin-releasing factor (CRF) is
responsible for the activation of the hypothalamic-pituitary-
adrenal (HPA) axis, which makes the CRF system a major
regulator of endocrine and behavioral responses to stress [22].
Subsequent studies have since revealed the involvement of the
CRF pathway in the development of anxiogenic traits during drug
withdrawal phase [23]. Since anxiety is the most visible trait and
potentially the major driving force in precipitating relapses, the
ability to manipulate CRF signaling may yield therapeutic
benefits. CRF signaling is mediated through the activities of two
distinct G-protein coupled receptor subtypes, known as CRF-R1
and CRF-R2 [24,25]. Indeed, studies have demonstrated the
ability of CRF receptor antagonists in reducing negative
motivational effects during withdrawal phase [26,27]. The
attenuation of aversive effects of opiate withdrawal in CRF-R1
and CRF-R2 deficient mice further validates the role of the CRF
pathway in addiction and withdrawal [28,29].
Dynorphin is a kappa-opioid receptor system (KOR) activating
opioid peptide implicated in several stress-induced behavioral
responses including anxiety, depression and drug seeking behav-
iors [30]. Studies in different animal models have also ascertained
the role of dynorphin and the KOR pathways in reinstatement of
drug seeking behaviors [31]. Several studies have collectively
established the relationship between the CRF and dynorphin
pathways by showing that activation of CRF receptors provokes
the downstream release of dynorphin, leading to the dysphoria
state commonly associated with drug withdrawal [32]. It is
therefore plausible that stress-induced anxiety and reinstatement
of drug seeking is predominantly mitigated through a CRF-
induced KOR dependent pathway [33].
Using zebrafish as a model system, we conducted a series of
experiments to gain further insights into the actions of mitragynine
during morphine withdrawal phase. We showed that mitragynine
was able to reduce anxiogenic swiming behaviors and concomi-
tantly lower whole body cortisol in morphine-withdrawn zebrafish.
Real-time gene expression analysis also revealed a reduction in the
expression of CRF-R1, CRF-R2 and prodynorphin (PDYN) genes
when morphine-withdrawn zebrafish were exposed to mitragynine.
Materials and Methods
Fish maintenance
Wild type zebrafish (Danio rerio) were maintained in
16 cm610 cm627 cm tanks in a stand alone automated zebrafish
housing system (Techniplast, Italy). Water temperature was
maintained at 27–28uC and tanks were located in a room with
12 h light/dark cycle. Fish were fed twice per day with live brine
shrimp and commercial fish pellets (Sanyu, Malaysia). Breeding
and embryo rearing were as described by Westerfield [34]. Test
animals were obtained from in-house population. For all
experiments, 4–5 months old adult male and female zebrafish
(50–50) were used [17].
Conditioned place preference (CPP) for morphine test
The CPP test was carried out to validate the preference
behavior for morphine in zebrafish [18,35]. Tests were conducted
in an isolated room between 1000 h to1800 h. The CPP tank was
sized at 20.5 cm612.5 cm611 cm and divided into 2 halves,
consisting of a white half and a black-dotted half, respectively.
During day 1 of the CPP experiment, a baseline preference test
was carried out to determine the initial preference of fish towards
the preferred compartment of the CPP tank [35]. Test animals
were fed in the usual manner in the morning, with behavioral
observations conducted 2 h later. Test fish was first introduced
into the middle section of the test tank, allowed to habituate for
10 min before a 5 min visual recording to determine its baseline
preference for which half of the tank.
Conditioning of fish with morphine was carried out by exposing
fish to morphine for 30 min in its respective non-preferred
compartment [35]. Fish that showed a baseline preference for the
white half was gently netted to the dotted morphine side and left
for 30 min, followed by exposure to system water on the white side
for another 30 min. Similarly fish that showed baseline initial
preference on dotted side were treated as above in a reversed
manner for the same duration of time. Fishes were then returned
to holding tank for 24 h without any feeding, to avoid unwanted
variable response [35]. Only individuals with baseline preference
between 50.1 and 79.9% for either side were chosen for
subsequent experiments. This was done by excluding those with
.80% time spent on either side during the baseline preference
tests.
On day 2, the animal was reintroduced in the CPP tank to
determine its preference for the white or dotted side in a morphine
free environment with a 5 min visual recording. Result was
expressed as percentage of changes in preference, calculated as
percentage of time in morphine side after conditioning minus the
percentage of time in baseline preference. For control, the whole
CPP procedure was same, except that the fishes were exposed to
non-morphine water during conditioning.
Separate tanks and fish nets were used during all transferring
process to prevent the cross-contamination [35]. A total of three
morphine concentrations (0.5, 1.5 and 3 mg/L) were tested.
Morphine solutions were prepared by dissolving a morphine stock
solution (10 mg/L) with system water. All behaviors of the fish
during test was recorded using a Noldus EthoVision XT 8 system
(Noldus Information Technology, Netherlands) with the camera
placed approximately 1.2 m above the test tanks.
Morphine treatment, withdrawal inducement and
mitragynine preparation
The following protocol was used for morphine addiction and
withdrawal. A total of 10 adult fish (1.160.2 g) was randomly
chosen from the holding tank and chronically treated in treatment
tank containing 1.5 mg/L of morphine sulphate (Lipomed,
Germany) for two weeks [36]. In order to induce morphine
withdrawal, fish were treated with 1.5 mg/L morphine for 2 weeks
and transferred to system water for 24 h before experiment [36].
For control group, fish were kept in system water for two weeks,
followed by an additional 24 h. For mitragynine treatment,
morphine withdrawn fish were exposed to mitragynine (1 mg/L
and 2 mg/L) for 1 h before subjected to the system water prior to
experiment. For acute mitragynine treatment, fish were treated
with 1 mg/L and 2 mg/L of mitragynine for 20 min before
initiation of behavior testing. Feeding was carried out as usual
throughout the whole treatment duration. For all experiments,
adult fish aged 4–5 months old and a 50:50 mixture of male:female
fish were used.
Mitragynine was obtained from fresh leaves of M. speciosa
sampled from Kedah and Perlis, Malaysia. Upon authentication,
samples were deposited at Malaysian Institute of Pharmaceuticals
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35-C1). Leaves were washed and dried in oven at 40uC for 3 days,
prior to grinding into powder form. A total of 300–400 g of the
dry powder was Soxhlet extracted in methanol at 40uC for 28 h.
The suspension was filtered and methanol was removed by rotary
evaporator. The methanol extract was further dissolved in 10%
(v/v) acetic acid solution, filtered and washed with hexane. The
solution was then treated with 25% (v/v) ammonia solution to
raise pH to 9, followed by extraction with dichloromethane.
Extracts were evaporated with rotary evaporator to produce the
alkaloid extract. Isolation of mitragynine from alkaloid extract was
carried using analytical and preparative HPLC as described
elsewhere [37].
Novel tank diving tests
Novel tank diving tests were performed according to Cachat
et al. [36]. After the procedures of morphine treatment or
morphine withdrawal or mitragynine treatment of morphine-
withdrawal as described above, fish were placed in a
16 cm610 cm627 cm tanks filled with system water. Location
of tests and visual system were as described above. Behavior of
each fish was recorded for 6 min and the following endpoints were
assessed: time spent in top of the tank (s); latency to top (amount of
time it takes the fish to cross into the upper half of the tank;
average entry duration (total time spent at top divided by the
number of entries), top and bottom ratio, number of freezing bouts
and duration of freezing bouts. Freezing was defined as total
absence of movement except for the gills and eyes, for 1 s or longer
[36]. The novel diving tests were also conducted on fish exposed to
acute treatment of mitragynine.
Whole body cortisol assay
An assay developed to measure zebrafish whole body cortisol
was used to measure cortisol in fish exposed to chronic morphine
treatment, morphine withdrawal and exposure of mitragynine on
morphine-withdrawn fish [17]. Fish were immediately frozen in
liquid nitrogen upon end of chemical treatment and stored at
220uC. Whole body was homogenized in 500 mL of ice-cold 16
PBS and the homogenizer rinsed with another 500 mL of PBS.
The resulting homogenate was transferred to a glass tube, cortisol
was extracted with diethyl ether (Fisher Scientific, USA), twice,
and reconstituted with 1 mL of PBS. Enzyme-linked immunosor-
bent assay (ELISA) approach was used to quantify the cortisol
concentration, performed using a commercially available human
salivary cortisol assay kit (IBL International GMBH, Hamburg
Germany). Absorbance was measured with a EnVision-2104
Multilabel Reader (Perkin Elmer, USA) using the manufacturer’s
software. The cortisol concentration was determined from
standard curve derived from absorbance values of standard
cortisol concentration curve. Concentrations were calculated as
relative concentration per gram of body weight for each fish.
Real-time PCR for mRNA expression analysis of zebrafish
CRF-R1, CRF-R2 and PDYN
Fish subjected to chronic morphine treatment, morphine
withdrawal and exposure of mitragynine on morphine-withdrawn
fish were sampled for expression analysis of zebrafish CRF-R1,
CRF-R2 and PDYN genes using real-time PCR. Brain tissues
were dissected from the liquid nitrogen frozen fish and kept at
280uC prior to RNA isolation. Total RNA was isolated using
TRIzolH reagent (Invitrogen, CA, USA) according to manufac-
turer’s protocol. The integrity and purity of the RNA was verified
by gel electrophoresis and ratio of 260/280 absorbance reading.
RNA samples were stored at 280uC for downstream applications.
Specific primers for CRF-R1, CRF-R2, PDYN and b-actin
were designed according to zebrafish sequences in GenBank
(Table 1). Changes in the gene expression were quantified using
semi-quantitative real time PCR approach. Before performing the
PCR, total RNA was treated with RNase-free DNase (Promega
Madison, WI, USA) in order to remove the genomic DNA
contamination. PCR amplification was performed by using
iScript
TM One-Step RT-PCR kit on a CFX96
TM Real-time
PCR detection system (Bio-Rad, USA). Gradient PCR was first
carried out to determine the optimized annealing temperature for
each set of primers. Efficiency test was carried out to evaluate the
performance of the respective primers sets. Real-time PCR
amplification was carried out in a total volume of 25 mL mixture
containing 12.5 mLo f2 6 SYBR Green Reaction Mix, 0.75 mL
(0.3 mM) of each primer, 0.5 mL of iScript Reverse Transcriptase,
9.5 mL of nuclease-free H20 and 1 mL of RNA template (100 ng).
The PCR cycle was as follows: cDNA synthesis at 50uC for
10 min, default cycling conditions were used for reverse
transcriptase inactivation at 95uC for 5 min, followed by 40 cycles
of denaturation at 95uC for 10 s and annealing at 63uC for 30 s.
Melt curve analysis was carried out to determine the specificity of
the PCR products. The expression level of genes was calculated by
using CFX Manager
TM software (BioRad, USA), with normal-
ization to housekeeping gene b-actin. Three independent
experiments were carried out and each experiment performed in
three analytical replicates.
Statistical analysis
All data were presented as mean 6 SEM (standard error of
mean) of three independent experiments. Statistical analysis was
performed using the one way analysis of variance (ANOVA) and
where applicable, ranked by Tukey’s multiple comparison tests.
Values of p,0.05 were considered significant.
Ethics statement
All procedures involving animal handling in this study complied
with the guidelines of the Animal Ethics Committee, Malaysian
Institute of Pharmaceuticals and Nutraceuticals, Malaysian Minis-
try of Science, Technology and Innovation and was approved by
the same commitee under the File ID of PA/ACSC/002/2011.
Table 1. Primer sequences used for semi-quantitative real
time PCR gene expression study of corticotropin-releasing
factor type 1 receptor, corticotropin-releasing factor type 2
receptor and prodynorphin.
Gene Primer sequences 59-39
GenBank Accession
number
CRF-R1 F: GGTGGCTGAGGGTGATGAAG XM691254
R: AGGCTTTCCAGTTCCCCAAA
CRF-R2 F: CACATGGGCACTGAAGAGCA XM002667848
R: TGAGGGCTCCAACAGACACA
PDYN F: TGAGCCAGGCAGATTGTTCA AF057040
R:TCTCCGTCTGCGCCTGTATT
b-actin F: GGATTCGCTGGAGATGATGC NM001001831
R: CGTGCTCGATGGGGTACTTC
Each sequence is listed starting from the 59-end and its corresponding
sequence ID are provided. F, forward primer; R, reverse primer.
doi:10.1371/journal.pone.0028340.t001
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Zebrafish exhibit CPP towards morphine
We first showed that zebrafish do not display significant
preference for either dotted or white compartment (Figure 1A). In
addition, control fish showed no differences in place preference
before and after conditioning (Figure 1B). In comparison,
morphine treatment at 0.5 mg/L and 1.5 mg/L enhanced the
animal preference over an initially non-preferred compartment
(Figure 1C). Reduced preference was obtained at the highest
concentration (3 mg/L) (F3,60=8.109, P,0.001). This experi-
ment validates the association of zebrafish with morphine as a
positive stimulus at 1.5 mg/L, and this concentration was
subsequently used in subsequent addiction and withdrawal
experiments.
Effects of morphine, morphine withdrawal and
mitragynine on anxiety-related behavior in zebrafish
Figure 2 shows the effect of two weeks of chronic morphine
treatment, morphine withdrawal and mitragynine treatment of
morphine-withdrawn fish on several behavioral indices of anxiety.
Novel tank diving tests showed that there was a change in terms of
the time spent at top and top:bottom ratio between control and 2
weeks morphine treatment groups. No other apparent changes in
other swimming behavior were observed. Overall, withdrawal
from morphine produced strong anxiogenic behaviors in zebrafish.
More specifically, morphine-withdrawn fish showed inferior
explorative behavior as indicated by reduced amount of time
spent at top of tank (F3,82=24.097, P,0.001), increased latency to
reach the top of tank (F3,82=3.445, P=0.020), reduced average
entry duration (F3,82=7.243, P,0.001), and reduced top to
bottom ratio (F3,71=5.931, P=0.001). In addition, higher freezing
duration (F3,25=9.026, P,0.01) and freezing bout values
(F3,82=0.619, P=0.605) also occurred in morphine-withdrawn
fish. Collectively, these parameters indicate higher anxiety levels in
morphine-withdrawn fish. In comparison, mitragynine treatment
on morphine-withdrawn fish resulted in fish displaying swimming
behaviors comparable to that of the control or morphine treated
fish. There was no significant difference between control and
mitragynine treated withdrawn fish for all the six swimming
behaviors. Taken together, results from the novel tank diving tests
imply that mitragynine attenuates stress-related behaviors in
morphine-withdrawn zebrafish. Acute treatment of zebrafish with
mitragynine, in particular at 2 mg/L resulted in changes in all the
swimming behaviors (Figure 2B). For treatment with 1 mg/L,
significant differences in terms of latency to top (F2, 65=5.243,
P=0.008), time in top (F2, 59=29.880, P,0.001) and top:bottom
ratio (F2, 59=18.912, P,0.001) as compared to control fishes were
recorded, indicating a mild anxiolytic effect.
Mitragynine lowers zebrafish whole-body cortisol
production during morphine withdrawal phase
Significant elevation in cortisol level was detected in morphine-
withdrawn zebrafish as compared to both control and chronic
morphine treatment (Figure 3). However, exposing morphine-
withdrawn fish to mitragynine at both concentrations significantly
reduced whole-body cortisol level in zebrafish (F4,89=12.134,
P,0.001).
Figure 1. Conditioned Place Preference (CPP) test for morphine
in adult zebrafish. (A) Baseline preference of fish between dotted vs.
white compartment as shown by percentage of initial time spend in
compartment (n=23). (B) Preference behavior responses in the CPP
tanks for control group as shown by percentage of time spent in
conditioning compartment before (white bar) and after (grey bar)
conditioning. (n=15). (C) Place preference behavior of adult zebrafish
treated different morphine concentration (Control, n=15; 0.5 mg/L,
n=18; 1.5 mg/L, n=16; 3 mg/L, n=15). Mean values were subjected to
one way ANOVA and where applicable, ranked by Tukey test (P,0.05);
mean percentage values with same letter are not significantly different.
doi:10.1371/journal.pone.0028340.g001
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morphine treated, morphine-withdrawal and
mitragynine treatment of morphine-withdrawn fish
Transcripts of CRF-R1 increased significantly during chronic
morphine treatment and reduced slightly during withdrawal phase
(F3,8=6.373, P=0.016) (Figure 4A). Treatment with mitragynine
however reduced the expression to the level comparable with
control fish. As for CRF-R2, significant high level of expression
was obtained in morphine treated and morphine-withdrawn fish
respectively while mitragynine treatment significantly lowered the
level of CRF-R2 transcripts (F3,12=37.219, P,0.001) (Figure 4B).
In general, PDYN showed a similar expression pattern with CRF-
R1, with the highest expression in chronic treatment, followed by
withdrawal and mitragynine treatment (F3,4=12.158, P=0.018)
(Figure 4C).
Discussion
The harshness of opiate withdrawal symptom requires proper
management strategies, which may include relieving stressful
symptoms during withdrawal phase, to avoid relapse into
addiction. Leaves of M. speciosa have been long used as a form
of self-remedy among drug addicts to provide respite from
Figure 2. Effects of morphine treatment, morphine withdrawal and mitragynine on swimming behavior in adult zebrafish using the
novel tank diving test. (A). Effect of two weeks chronic morphine treatment (1.5 mg/L), 24 h morphine withdrawal and morphine withdrawal in
presence of 2 mg/L mitragynine on swimming behavior of zebrafish. (Control, n=17; morphine treatments, n=25; morphine withdrawal, n=22;
morphine withdrawal+mitragynine, n=22). All data were presented in mean 6 SEM. Mean values were subjected to one way ANOVA and where
applicable, ranked by Tukey test (P,0.05); mean values with same letter are not significantly different. (B) Effect of 20 min acute mitragynine
treatment (1 mg/L and 2 mg/L) on swimming behavior of zebrafish. (Control, n=21; 1 mg/L mitragynine, n=20; 2 mg/L mitragynine, n=21). All data
were presented in mean 6 SEM. Mean values were subjected to one way ANOVA and where applicable, ranked by Tukey test (P,0.05); mean values
with same letter are not significantly different.
doi:10.1371/journal.pone.0028340.g002
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and use of this plant, much remains to be understood of M.
speciosa’s ability to attenuate withdrawal symptoms [10,13]. The
zebrafish is a proven upcoming model for understanding drug
withdrawal [38,39]. Here, we investigate the influence of
mitragynine, the main predominant alkaloid in M. speciosa on
stress-related swimming behaviors, whole-body cortisol production
and expression of CRF-R and PDYN genes in morphine-
withdrawn zebrafish.
We first established the effect of morphine treatment on CPP
behavior in adult zebrafish. Overall, our result recapitulates
findings from earlier studies reporting the ability of morphine and
other substances to enhance adult zebrafish’s robust preference for
an initially non-preferred compartment [18,40]. The work of Lau
et al. also showed increase in zebrafish brain morphine
concentration after 15 min morphine exposure [18]. Using a
series of novel tank diving tests, we then demonstrated that
withdrawing zebrafish from morphine after a period of chronic
exposure result in strong anxiogenic effects on zebrafish swimming
behavior. These observations are consistent with a similar study
reporting decreased exploratory behavior, reduced top transitions
and increased erratic movement, freezing frequency and duration
in zebrafish withdrawn from morphine [17]. Interestingly, the
application of mitragynine significantly reduced the anxiety effects
in morphine-withdrawn zebrafish, with several behaviors such as
time in top of tank, latency to top and freezing duration being
restored to levels before the onset of withdrawal treatment. These
results parallel the known ability of M. speciosa in diminishing
withdrawal symptoms [10]. Results from acute exposure of
mitragynine alone seemed to indicate a mild change in swimming
behavior effect. Elsewhere, it was reported that acute treatment of
zebrafish with a range of M. speciosa leaf extract concentration
resulted in mild sedative effect without any clear anxiolytic effect
[39].
In teleosts, cortisol is the major product of physiological
response to stress and is commonly used as a primary stress
Figure 3. Effect of two weeks chronic morphine treatment (1.5 mg/L), 24-h morphine withdrawal and morphine withdrawal in
presence of mitragynine (1 mg/L or 2 mg/L) on whole-body cortisol (mg/g fish). Data are presented as mean 6 SEM. (Control, n=16;
morphine treatments, n=14; morphine withdrawal, n=21; 1.0 mg/L Mitragynine, n=23; 2 mg/L Mitragynine, n=20). Mean values were subjected to
one way ANOVA and where applicable, ranked by Tukey test (P,0.05); values with same letter are not significantly different.
doi:10.1371/journal.pone.0028340.g003
Figure 4. Effect of two weeks chronic morphine treatment (1.5 mg/L), 24-h morphine withdrawal and morphine withdrawal in
presence of 2 mg/L mitragynine on the mRNA expression of CRF-R1, CRF-R2 and PDYN in zebrafish. Data are presented as mean 6 SEM
of three independent experiments. Mean values were subjected to one way ANOVA and where applicable, ranked by Tukey test (P,0.05); mean
percentage values with same letter are not significantly different.
doi:10.1371/journal.pone.0028340.g004
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treatment of morphine did not influence the cortisol level in the
zebrafish, withdrawal from morphine significantly increases the
cortisol level. Elsewhere, increased zebrafish whole-body cortisol
secretion has been associated with withdrawal from several
addictive substances, including ethanol and morphine [17]. In
human, withdrawal from various addictive substances also elevates
cortisol production [44,45]. Furthermore, we showed that
mitragynine significantly lowered whole-body cortisol production
in morphine-withdrawn adult zebrafish, demonstrating an associ-
ation between the attenuation of anxiogenic behaviors and lower
production of cortisol in the presence of mitragynine. Adminis-
tration of mitragynine also reduced corticosterone in mice, which
gives an indication on the ability of this compound as
antidepressant agent [15].
The release of cortisol is a result of a series of hormonal
regulated events involving the activation of the hypothalamus-
pituitary-interrenal axis, with the CRF acting as the initial
hormone in the signaling cascade [46]. In zebrafish, the CRF is
localized in different parts of the embryonic zebrafish brain,
including telencephalon, preoptic region, hypothalamus, posterior
tuberculum, thalamus, epiphysis, midbrain tegmentum, and
rostral hindbrain [47]. In this present study, treatment with
morphine increased the mRNA expression of both CRF-R1 and
CRF-R2, which is consistent with observations in rats [26]. The
expression of CRF-R1 was significantly lower in morphine-
withdrawn fish compared to chronic morphine treatment, while
no significant difference was observed for CRF-R2. This is
reminiscent of the findings of Iredale et al. [26], where morphine-
withdrawal reduced CRF-R1 expression in the rat brain. It has
been speculated that the downregulation of CRF receptors during
withdrawal is a homeostatic compensatory response against the
overactivation of CRF-R1 during withdrawal, which adaptively
lessens the arduous conditions of drug withdrawal. [26,48,49].
During chronic opiate exposure, an increase in cellular adenosine
39,59-monophosphate (cAMP) activities is a celluar measure to
counter the inhibition of cAMP by opiates [50]. Therefore, the
downregulation of CRF-R1 mRNA expression during morphine
withdrawal is also a postulated homeostatic adaptation to
counteract the overactivation of cAMP [51]. In addition, we also
showed here that mitragynine significantly lowered the mRNA
levels of both CRF-R1 and CRF-R2 in morphine-withdrawn fish,
a trend that correlates with the attenuation of both anxiety
behavior and whole cortisol production. The lower mRNA levels
for both receptors in zebrafish treated with mitragynine is of
importance, given the known fact that activation of both these
receptors is shown to be partially responsible for stress-induced
reinstatement of drug seeking [28,52]. To our knowledge, this is
the first study implicating a possible link between mitragynine and
the CRF pathway in the mitigation of withdrawal symptoms,
although the actual mechanism remains to be determined.
The zebrafish prodynorphin (PDYN) gene is highly homologous
to the mammalian dynorphin and is capable of activating all
known zebrafish opioid receptors [53]. In mice, both chronic
morphine treatment and withdrawal increase dynorphin expres-
sion, which denote the importance of this protein in addiction and
withdrawal [54]. In addition, the blockage of dynorphin with
known antagonist decreased the severity of withdrawal [54]. Here,
we showed chronic morphine treatment increased expression of
zebrafish PDYN, while withdrawal from morphine and especially
treatment with mitragynine significantly decreased the transcript
levels. The reduced levels of zebrafish PDYN mRNA in presence
of mitragynine could possibly explain the reduced stress-liked
swimming behaviors displayed in the novel tank diving test as
dynorphin, alongside CRF, is also a key mediator of stress-induced
drug relapse during withdrawal [31]. In addition, the release of
dynorphin by the activation of CRF receptors have been
implicated as the cause of dysphoria state commonly associated
with drug withdrawal [32]. Taking this into consideration, the
lower expression of PDYN in zebrafish exposed to mitragynine
could probably be the result of reduced expression of both the
CRF receptors. In addition, it is worth mentioning that
mitragynine possess affinity towards kappa-opioid receptors, which
may hypothetically be an avenue for attenuation of negative
withdrawal effects [10,55].
In conclusion, we showed here the capacity of mitragynine to
diminish stressful swimming behaviors and cortisol production in
morphine-withdrawn zebrafish. In addition, using gene expression
studies, we also showed for the first time that the attenuation of
withdrawal syndrome by mitragynine might involve both the HPA
and KOR pathways.
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